18 Jan Cynata Therapeutics
Ross Macdonald, Ph.D., CEO
April 20 | 11:00am | Gaudi 3 Ballroom
Melbourne, Australia
(ASX: CYP)
In-Person Presentation
Cynata Therapeutics is a clinical-stage regenerative medicine company developing a therapeutic mesenchymal stem cell platform technology, Cymerus™, utilizing induced pluripotent stem cells. A successful world-first clinical trial in graft-versus-host disease met all safety and efficacy endpoints with a Phase II trial expected to commence in the U.S. in 2022. A Phase III clinical trial in osteoarthritis and a Phase I/II clinical trial in COVID-19 commenced in 2020 and a Phase I/II trial in diabetic foot ulcers will commence in late 2021. The company’s major shareholders include BioScience Managers, a leading global healthcare institutional investor, Fidelity, and Fujifilm. The company’s proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of multi-donor derived MSCs for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale.
